AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bionano Genomics, Inc. Director's Dealing 2018

Aug 27, 2018

35041_dirs_2018-08-27_e3729412-8738-4be9-a2da-c4cbe5fba2b4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioNano Genomics, Inc (BNGO)
CIK: 0001411690
Period of Report: 2018-08-23

Reporting Person: TWOMEY CHRISTOPHER J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-23	Common Stock	P	10000	$6.125	Acquired	10000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-23	Common Stock Warrants (right to buy)	$6.125	P	10000	Acquired	2023-08-21	Common Stock (10000)	Direct

Footnotes

F1: Units purchased in the Issuer's Initial Public Offering for $6.125 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock.

F2: 9/21/18 or such earlier date as Roth Capital Partners LLC, as representative of the underwriters in the Company's Initial Public Offering, shall determine.